Information Disclosure
-
04 2025.06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
-
29 2025.05
Next Day Disclosure Return
-
29 2025.05
COMPLETION OF PLACING OF H SHARES
-
27 2025.05
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR TELITACICEPT FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN CHINA
-
26 2025.05
TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE UNDER THE BOARD OF THE COMPANY
-
26 2025.05
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE UNDER THE BOARD OF THE COMPANY
-
26 2025.05
TERMS OF REFERENCE OF THE AUDIT COMMITTEE UNDER THE BOARD OF THE COMPANY
-
26 2025.05
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
-
26 2025.05
CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE
-
26 2025.05
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
-
27 2025.03
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024
-
04 2024.12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
-
05 2024.11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
-
29 2024.10
2024 THIRD QUARTERLY REPORT
-
07 2024.10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
-
25 2024.09
2024 Interim Report
-
05 2024.09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
-
16 2024.08
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
-
06 2024.08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
-
06 2024.08
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Corporate Governance
-
28 2024.06
ARTICLES OF ASSOCIATION
-
19 2022.04
Constitutional Documents ARTICLES OF ASSOCIATION
-
31 2022.03
Constitutional Documents - ARTICLES OF ASSOCIATION
-
06 2020.11
Constitutional Documents - ARTICLES OF ASSOCIATION
-
06 2020.11
SHAREHOLDERS’ COMMUNICATION POLICY
-
06 2020.11
PROCEDURES FOR SHAREHOLDERS TO NOMINATE AN INDIVIDUAL AS A DIRECTOR OR A SUPERVISOR OF THE COMPANY
-
06 2020.11
BOARD DIVERSITY POLICY
IR Contacts
58 Beijing Middle Road, Yantai Shandong, China.
-
- Company Wechat